New Book Announcement –Perinatal Cardiology Part 1 and Part 2

In Perinatal Cardiology, fetal cardiology experts provide key information on tools for fetal evaluation through echocardiography / cardiac ultrasonography, with a primary focus on the nature and prenatal detection of structural and functional cardiac heart defects (CHDs). In this two-part book, readers will find details about different types of fetal cardiac abnormalities along with important updates on the diagnosis, management, planning delivery, and postnatal treatment in CHD cases. This information is supplemented with guidelines for the clinical management of patients with a fetus affected by cardiovascular defects, and surgical procedures in neonates.

Key features:

  1. -presents information gathered by experts in perinatal cardiology, organized into 26 topic-based chapters
  2. -explores the cardiac development, fetal cardiovascular hemodynamics, genetic and environmental factors associated with congenital heart defects (CHD), perinatal management, planning delivery, and postnatal treatment of newborns with CHD
  3. -presents information about normal cardiac functions and heart defects to give readers a clear and detailed picture of abnormal cardiac function
  4. -presents information about perinatal ultrasound physiology
  5. -gives practical guidelines for ultrasound and echography parameters required for evaluating fetal heart anatomy and diagnosing diseases
  6. -includes a new system of classifying prenatal CHDs based on the stratification of the risk level of care
  7. -features a straightforward and accessible style of presentation suitable for all readers
  8. -provides references in each chapter for further reading

Part 1 of this two-part set covers the basics of perinatal cardiology which chapters that introduce readers to CHD classification, fetal heart and placental physiology and pathology, diagnosis of fetal cardiac malposition and anomalies and some congenital heart defects such as septal defects, cardiac anomalies of the left and sec sides, conotruncal anomalies and aortic arch anomalies.

Part 2 of this two-part set delves into different fetal anomalies such as ventricular inflow anomalies, myocardial and pericardial diseases, cardiac tumors, extra-cardiac conditions, cardiac failure, and environmental factors associated with CHD. The latter chapters cover clinical topics such as labor management for patients bearing a child with CHD, fetal cardiac interventions, clinical management of neonates with CHD and postnatal surgery.

Perinatal Cardiology is an essential reference for postgraduate medical students seeking to improve their knowledge of fetal and pediatric cardiology as part of their residency and professional training. The book equips readers with the information necessary to understand the role of the perinatal cardiologist and goes further to facilitate the ability to perform adequate risk assessments for fetal CHD.

Read out the full version: Part 1

Part 2

AIMS & SCOPE – Current Vascular Pharmacology

Aims & Scope:

Current Vascular Pharmacology publishes clinical and research-based reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research.

Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).

 

cvp-flyer.jpg

 

For more details, please visit: https://benthamscience.com/journals/current-vascular-pharmacology/aims-scope/#top

ARTICLE TO READ ON World Heart Day, 2018!

The Role of Myocardial Collagen Network in Hypertensive Heart Disease

 

Author(s): Javier Diez, Begona Lopez, Arantxa Gonzalez, Ramon Querejeta.

 

Abstract:

It is time to recognize that the quality, not quantity, of myocardium in hypertensive heart disease is responsible for adverse cardiovascular events. Experimental and clinical available data indicate that myocardial fibrosis due to the exaggerated accumulation of collagen type I and type III fibers predisposes to an enhanced risk of diastolic and/or systolic ventricular dysfunction, symptomatic heart failure, ischemic heart disease, and arrhythmia in patients with hypertensive heart disease. Thus, management of these patients must not only focus on detection and regression of left ventricular hypertrophy. Far more sensible are interventions aimed to detect and target hypertensive myocardial fibrosis. The available data on the use of biochemical and/or imaging methodologies to address excessive accumulation of collagen fibers in the myocardium of hypertensive patients are promising. On the other hand, preliminary data suggest that the goal of reducing myocardial fibrosis is achievable in patients with hypertensive heart disease treated with specific anti hypertensive agents. Collectively, these findings set the stage for larger trials where-in noninvasive measures and reparative strategies of myocardial fibrosis to prevent heart failure could prove useful.

 

For more details, please visit: http://www.eurekaselect.com/58592

Most Accessed Article – Psychological Stress in Pathogenesis of Essential Hypertension – Current Hypertension Reviews

Journal: Current Hypertension Reviews

Author(s): Alexey V. Ushakov, Vera S. Ivanchenko, Alina A. Gagarina.

Graphical Abstract:

 

Abstract:

The article represents literature review and provides evidence for psychological stress to play essential role in the development of arterial hypertension. The pathogenesis of hypertension is complex with a significant diversity and variability of the mechanisms involved in individual patient. In this regard, the determination of specific pathogenic pathways underlying sustained blood pressure elevation in each patient would substantially individualize therapeutic approaches, and hence increase the effectiveness of treatment. Psychological stress is proposed as a significant factor contributing to the development of hypertension. Global urbanization, sedentary lifestyle, daily stress at workplace, lack of physical activity and social support lead to increased anxiety, uncertainty, and finally to chronic mental and emotional stress. This review provides information about alterations in neuroendocrine and immune systems as the main pathogenic pathways linking psychological stress and hypertension. Endothelial dysfunction is considered not only as a consequence but also a primary factor causing prohypertensive state. Moreover, physical inactivity is discussed as one of the plausible mechanisms playing a key role in the development of hypertension in modern lifestyle conditions. Particularly the loss of connection between psychosocial strain and physical activity may underlie the deleterious effect of stress on cardiovascular and metabolic health.

To access the article, please visit: http://www.eurekaselect.com/148822/article

Article by Disease – “Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study”

Article by Disease on “Cardiology

Abstract:

Objective: We evaluated the safety and efficacy of hypertension management with Coveram (perindopril/amlodipine combination) in patients with uncontrolled blood pressure (BP). All patients were on previous angiotensin receptor blocker (ARB) treatment.

Methods: This was a 3 country, multi-centre (7 cities), open-label, observational study in the Arabian Gulf. Patients (18 years) were recruited between October 2012 and November 2013 and followed-up for 3 months after enrolment. Outcomes included changes in BP from baseline and BP goal attainment rates as per Joint National Committee- 8 (<140/90 mmHg for diabetics and those <60 years of age and <150/90 mmHg for those 60 years of age without diabetes). Medication tolerance was also assessed from both patient and physician perspectives.

Results: Hypertensive patients (n=760; mean age: 51±10 years; 67% were males) were included. A total of 178 patients (23%) were lost to follow-up. The perindopril/amlodipine combination was associated with an overall reduction in systolic BP (SBP) (31 mmHg; p<0.001) and diastolic BP (DBP) (18 mmHg; p<0.001) from baseline. An overall BP control rate was achieved in 87% (n=507) of the participants. There were significant incremental BP reductions with dose up-titration, especially SBP (p<0.001). Those with high SBP (>180 mmHg) at baseline were associated with a mean reduction of 59 mmHg (p<0.001). The perindopril/amlodipine combination had excellent tolerance levels over the study period from both patient and physician perspectives (at 99% and 98%, respectively; p<0.001).

Conclusions: The perindopril/amlodipine combination is an effective and well tolerated anti-hypertensive option in patients on previous ARB treatment.

Read more: http://www.eurekaselect.com/node/144156/article

Article by Disease – “Beta-Blockers and Nitrates: Pharmacotherapy and Indications”

ARTICLE BY DISEASE ON “CARDIOLOGY”

Abstract:

Many clinically important differences exist between beta blockers. B1-selectivity is of clinical interest because at clinically used doses, b1- selective agents block cardiac b-receptors while having minor effects on bronchial and vascular b-receptors. Beta-adrenergic blocking agents significantly decrease the frequency and duration of angina pectoris, instead the prognostic benefit of beta-blockers in stable angina has been extrapolated from studies of post myocardial infarction but has not yet been documented without left ventricular disfunction or previous myocardial infarction. Organic nitrates are among the oldest drugs, but they still remain a widely used adjuvant in the treatment of symptomatic coronary artery disease. While their efficacy in relieving angina pectoris symptoms in acute settings and in preventing angina before physical or emotional stress is undisputed, the chronic use of nitrates has been associated with potentially important side effects such as tolerance and endothelial dysfunction. B-blockers are the firstline anti-anginal therapy in stable stable angina patients without contraindications, while nitrates are the secondline anti-anginal therapy. Despite 150 years of clinical practice, they remain fascinating drugs, which in a chronic setting still deserve investigation. This review evaluated pharmacotherapy and indications of Beta-blockers and nitrates in stable angina.

Read more: http://www.eurekaselect.com/node/127075/article

%d bloggers like this: